足月及近足月新生儿临床发作与脑电发作治疗效果的随机临床试验
该随机临床试验纳入212例胎龄≥35周、生后<48小时、存在脑病的新生儿,随机分为脑电发作组(ESG,治疗aEEG检测到的发作及临床发作)和临床发作组(CSG,仅治疗临床检测到的发作)。主要终点为2岁时死亡或严重残疾,ESG组38/86(44%)vs CSG组27/86(31%),OR 1.83(95%CI 0.96-3.49,P=0.14),差异无统计学意义;HIE亚组OR 1.77(95%CI 0.84-3.73,P=0.26)。认知评分ESG组更差(97.4 vs 103.8,均差-6.5,95%CI -1.2至-11.8,P=0.01)。结论认为,使用当前抗惊厥药治疗脑电和临床发作未显著降低2岁时死亡或残疾率。
要点
- 在脑病足月/近足月新生儿中,治疗aEEG检出的脑电发作未显著改善2岁无严重残疾生存(44% vs 31%,OR 1.83,95%CI 0.96-3.49,P=0.14)。
- ESG组认知评分较CSG组更差(97.4 vs 103.8,均差-6.5,95%CI -1.2至-11.8,P=0.01)。
- HIE亚组主要终点无显著差异(OR 1.77,95%CI 0.84-3.73,P=0.26)。
- 2岁评估前死亡:ESG组10/86(9%),CSG组4/86(4%)。
- 次要结局(达到全经口喂养时间、发作负荷、脑损伤评分)差异证据很少。
适用人群与场景
- 胎龄≥35周、生后<48小时、存在脑病的新生儿,在三级新生儿重症监护病房收治。
- 共212例随机,平均(SD)胎龄39.2(1.7)周,122例(58%)为男性;152例(72%)为中重度缺氧缺血性脑病(HIE),147例(84%)有脑电发作。
诊断标准与关键阈值
- 主要结局严重残疾定义:BSID-III任一发育领域评分低于澳大利亚均值2个标准差以上,或存在脑瘫、失明或耳聋。
处置流程与药物剂量
- ESG组:除治疗临床发作外,还治疗aEEG检测到的脑电发作。
- CSG组:仅治疗临床检测到的发作。
研究设计与关键结果
- 研究类型:随机临床试验,纳入212例,2012至2016年招募,随访至2岁。
- 主要终点:ESG组38/86(44%)vs CSG组27/86(31%)死亡或严重残疾,OR 1.83(95%CI 0.96-3.49,P=0.14)。
- HIE亚组主要终点:OR 1.77(95%CI 0.84-3.73,P=0.26)。
- 认知评分:ESG组平均(SD)97.4(17.7)vs CSG组103.8(17.3),均差-6.5(95%CI -1.2至-11.8),P=0.01。
- 2岁评估前死亡:ESG组10/86(9%),CSG组4/86(4%)。
- 次要结局(达到全经口喂养时间、发作负荷、脑损伤评分)差异证据很少。
证据类型、等级与局限
- 证据类型:随机临床试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,使用当前抗惊厥药治疗脑电和临床发作未显著降低异质性新生儿人群2岁时死亡或残疾率。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Seizures in the neonatal period are associated with increased mortality and morbidity. Bedside amplitude-integrated electroencephalography (aEEG) has facilitated the detection of electrographic seizures; however, whether these seizures should be treated remains uncertain.
OBJECTIVE: To determine if the active management of electrographic and clinical seizures in encephalopathic term or near-term neonates improves survival free of severe disability at 2 years of age compared with only treating clinically detected seizures.
DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial was conducted in tertiary newborn intensive care units recruited from 2012 to 2016 and followed up until 2 years of age. Participants included neonates with encephalopathy at 35 weeks' gestation or more and younger than 48 hours old. Data analysis was completed in April 2021.
INTERVENTIONS: Randomization was to an electrographic seizure group (ESG) in which seizures detected on aEEG were treated in addition to clinical seizures or a clinical seizure group (CSG) in which only seizures detected clinically were treated.
MAIN OUTCOMES AND MEASURES: Primary outcome was death or severe disability at 2 years, defined as scores in any developmental domain more than 2 SD below the Australian mean assessed with Bayley Scales of Neonate and Toddler Development, 3rd ed (BSID-III), or the presence of cerebral palsy, blindness, or deafness. Secondary outcomes included magnetic resonance imaging brain injury score at 5 to 14 days, time to full suck feeds, and individual domain scores on BSID-III at 2 years.
RESULTS: Of 212 randomized neonates, the mean (SD) gestational age was 39.2 (1.7) weeks and 122 (58%) were male; 152 (72%) had moderate to severe hypoxic-ischemic encephalopathy (HIE) and 147 (84%) had electrographic seizures. A total of 86 neonates were included in the ESG group and 86 were included in the CSG group. Ten of 86 (9%) neonates in the ESG and 4 of 86 (4%) in the CSG died before the 2-year assessment. The odds of the primary outcome were not significantly different in the ESG group compared with the CSG group (ESG, 38 of 86 [44%] vs CSG, 27 of 86 [31%]; odds ratio [OR], 1.83; 95% CI, 0.96 to 3.49; P = .14). There was also no significant difference in those with HIE (OR, 1.77; 95% CI, 0.84 to 3.73; P = .26). There was evidence that cognitive outcomes were worse in the ESG (mean [SD] scores, ESG: 97.4 [17.7] vs CSG: 103.8 [17.3]; mean difference, -6.5 [95% CI, -1.2 to -11.8]; P = .01). There was little evidence of a difference in secondary outcomes, including time to suck feeds, seizure burden, or brain injury score.
CONCLUSIONS AND RELEVANCE: Treating electrographic and clinical seizures with currently used anticonvulsants did not significantly reduce the rate of death or disability at 2 years in a heterogeneous group of neonates with seizures.
TRIAL REGISTRATION: http://anzctr.org.au Identifier: ACTRN12611000327987.
参考来源
- Hunt RW, Liley HG, Wagh D, et al. Effect of Treatment of Clinical Seizures vs Electrographic Seizures in Full-Term and Near-Term Neonates: A Randomized Clinical Trial. JAMA Netw Open. 2021. PMID: 34919132. doi:10.1001/jamanetworkopen.2021.39604
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。